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Abstract 
Aims: To measure cardiac tissue doses in left-sided breast cancer patients receiving supine 
tangential field radiotherapy with multileaf collimation (MLC) cardiac shielding of the heart and to 
assess the impact on target volume coverage  
Materials and methods: Sixty seven consecutive patients who underwent adjuvant radiotherapy to 
the left breast (n=48) or chest wall (n=19) in 2009/10 were analysed. Heart, left anterior descending 
coronary artery (LAD), whole breast and partial breast clinical target volumes (WBCTV and PBCTV) 
were outlined retrospectively (the latter only in patients who had undergone breast conserving 
surgery (BCS)). Mean heart and LAD *NTDmean and maximum LAD doses (LADmax) were calculated for 
all patients (*NTDmean is a biologically weighted mean dose normalised to 2Gy fractions using a 
standard linear quadratic model). Coverage of WBCTV and PBCTV by the 95% isodose was assessed 
(BCS patients only). 
Results: Mean heart NTDmean (SD) was 0.8 (0.3) Gy, mean LAD NTDmean 6.7 (4.3) Gy and mean LADmax 
40.3 (10.1) Gy. Coverage of the WBCTV by 95% isodose was <90% in 1 in 3 patients and PBCTV 
coverage <95% (range 78-94%) in 1 in 10 BCS patients.  
Conclusion: The use of MLC cardiac shielding reduces doses to cardiac tissues at the expense of 
target tissue coverage. Formal target volume delineation in combination with an assessment of the 
likelihood of local relapse (LR) is recommended in order to aid decisions regarding field and MLC 
placement.  
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Introduction 
 
The current UK standard for adjuvant breast radiotherapy in women who have undergone breast 
conserving surgery (BCS) or mastectomy uses tangential fields to treat the whole breast and chest 
wall respectively. Data from the Early Breast Cancer Triallists’ Collaborative Group most recent meta-
analysis suggest that adjuvant radiotherapy for breast cancer nearly halves a woman’s relative risk of 
breast cancer recurrence [1]. In addition, there is an absolute reduction in breast cancer mortality at 
15 years of about 4%. However, standard tangential breast radiotherapy fields risk giving unwanted 
irradiation to cardiac tissues. This problem is particularly significant in women receiving left breast 
radiotherapy, for whom the radiation dose received by cardiac tissues is greater than for those who 
receive right breast radiotherapy [2]. Consequently women who receive left breast radiotherapy 
have an increase in cardiac morbidity [3] and mortality [4] relative to right-sided patients. Increased 
awareness of late cardiac toxicity coupled with improvements in radiotherapy techniques has helped 
drive down the dose of radiation received by cardiac structures [5], but recent work suggests that 
mean heart dose (Gy) would need to be reduced to zero to eliminate the risk of late cardiac effects 
altogether [6]. 
 An approach used in many UK radiotherapy centres currently is to shield cardiac tissues using 
multileaf collimation (MLC) [2012 Royal College of Radiologists audit].  However, the use of MLC to 
shield the heart risks simultaneously shielding target tissue (see Figure 1). Most UK radiotherapy 
centres do not formally define a whole or partial breast clinical target volume for the purpose of 
whole breast radiotherapy field placement unless the patient is being treated within a clinical trial, 
and as such the compromise between target tissue coverage and heart dose is assessed visually, 
taking into account known patterns of local relapse and rates of cardiac morbidity [7]. 
In this study we set out to determine mean doses delivered to the heart and LAD using standard 
tangents with MLC shielding and to determine the proportion of women in whom a compromise is 
made between target and normal tissue irradiation. We also wanted to ascertain whether there was 
a relationship between the cardiac doses, operation type (BCS or mastectomy) and the position of 
the tumour bed within the breast.  
 
Materials and methods 
The study was approved by The Royal Marsden Hospital Audit Committee. Sixty-seven consecutive 
patients with left-sided breast cancer who underwent adjuvant radiotherapy to the breast or chest 
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wall between November 2009 and February 2010 were identified. The majority of patients who 
underwent BCS had titanium clips inserted into the tumour bed at the time of surgery [8]. 
 
Patient positioning, image acquisition radiotherapy planning and treatment 
All patients were scanned supine on a breast board, with arms extended above the head in supports 
(Med-Tec, Iowa, USA). Markers were placed bilaterally 1-2cm posterior to the mid-axillary line and 
aligned axially with a midline marker using lateral lasers. CT data (Philips Medical Systems, UK) was 
acquired without contrast in free-breathing from C6 to below the diaphragm. 
Standard tangential fields (inferior border of the clavicle (superior), 1cm below the inframammary 
fold (inferior), midline (medial) and anterior border of serratus anterior (lateral)) were applied in 
order to encompass breast or chest wall tissues. The depth of lung tissue included in the tangential 
fields was constrained to ≤2cm. Where cardiac tissues were present within the tangential fields, MLC 
leaves were positioned manually  in order to shield cardiac tissue. Each attending clinician approved 
the positioning of the tangential fields and used clinical judgement (based on risks of local relapse 
versus risk of late effects) to decide whether or not the MLC leaves should be retracted to increase 
coverage of target (breast or chest wall) tissues. Plans were produced which fulfilled ICRU 62 criteria 
[9]. Patients were treated using 6 or 10 MV photons with either 50 Gy in 25 fractions over 5 weeks 
or 40 Gy in 15 fractions over 3 weeks. 
 
Delineation of target tissues and organs-at-risk 
Partial and whole breast target volumes are not formally outlined in patients receiving standard off-
study whole breast or chest wall radiotherapy at our institution. This study, therefore, 
retrospectively delineated target tissues and organs-at risk (OAR). The whole breast clinical target 
volume (WBCTV) encompassed breast tissue visualised on CT (limited by pectoral fascia and 5mm 
from skin). In the majority of patients, titanium clips were inserted at the time of surgery and one or 
two clips were used to mark each of the six excision boundaries, according to a national protocol [8]. 
The tumour bed was defined using the tumour bed clips, and included any associated seroma or 
distortion of breast architecture. This volume was then expanded by 15mm in all directions (limited 
by the WBCTV) to form the partial breast clinical target volume (PBCTV). In patients without tumour 
bed clips, a tumour bed was only outlined if a seroma was present. The whole heart was outlined to 
the extent of the pericardial sac, in accordance with the UK National Cancer Research Institute 
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Intensity Modulated and Partial Organ RadioTherapy (IMPORT) study criteria [10]. The major blood 
vessels and the inferior vena cava were excluded. The LAD was outlined according to previously 
published criteria [5], including the left main coronary artery; where the LAD was difficult to 
visualise, its location was inferred from the course of the anterior interventricular groove. In 
accordance with current practice, the LAD was then expanded by 10mm to account for uncertainty 
in delineation, and movement related to respiration and the cardiac cycle [11]. All volumes were 
drawn by the same radiation oncologist, and the volumes of patients selected at random verified by 
a second radiation oncologist.  
 
Analysis 
All analysis was performed on the original clinical plans. Mean heart *NTDmean and LAD NTDmean and 
their standard deviations (SD) and range were calculated (*NTDmean is a biologically weighted mean 
dose normalised to 2Gy fractions using a standard linear quadratic model [12], α/β=3Gy [13,14]). 
The mean maximum LAD dose (LADmax), SD and range were calculated from dose volume histogram 
(DVH) data and normalised to 2Gy fractions. Spearman’s rank correlation coefficient was calculated 
to assess the relationship between mean heart NTDmean, LAD NTDmean and LADmax. 
Using DVH data, the percentage coverage of both the WBCTV and PBCTV by the 95% isodose was 
calculated.  Target volume coverage was assessed according to previously published criteria [15], 
such that ≥90% of the WBCTV and ≥95% of the PBCTV should be covered by the 95% isodose. The 
data were analysed to determine in what proportion of patients these constraints were met. Where 
PBCTV coverage constraints were not met, the individual plans were reviewed to assess the scope 
for improving PBCTV coverage (although not assessed formally by replanning).  
In patients who underwent BCS, the quadrant in which the tumour bed was located (the “index 
quadrant”) was noted and one-way ANOVA tests performed to compare the 95% isodose coverage, 
mean heartNTDmean, mean LAD NTDmean  and mean LADmax of these groups. The Mann-Whitney U test 
was used to compare the 95% isodose coverage, mean heart NTDmean, mean LAD NTDmean and mean 
LADmax of upper and lower half tumours and inner and outer half tumours in BCS patients (central 
tumours were excluded from the analysis). 
 
Results 
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48 (72%) patients underwent BCS and 19 (28%) underwent mastectomy. Cardiac shielding with MLC 
was used in 58% of patients. For all patients, mean heart NTDmean, (SD) and [range] were 0.8 (0.3) 
[0.0 – 2.1] Gy, mean LAD NTDmean 6.7 (4.3) [1.2 – 22.6] Gy and mean LADmax 40.3 (10.1) [4.6 – 51.3] 
Gy. Spearman correlations for mean heart and LAD NTDmean (r = 0.4, p = 0.03), mean heart NTDmean 
and LADmax (r = 0.3, p = 0.03) and mean LAD NTDmean and LADmax (r = 0.7, p < 0.01). 
WBCTV 95% isodose coverage was <90% in 17 (35%), range 73-100%. The PBCTV 95% isodose 
coverage was <95% in 10% of patients (range 78-100%). Three out of 5 patients in whom PBCTV 
coverage was <95% also had WBCTV coverage <90%. Reasons for compromised PBCTV coverage 
included shielding cardiac tissue, seroma close to skin (compromising dose in the build-up region) 
and large separation leading to difficulties with chest wall coverage, suggesting that factors in 
addition to cardiac shielding may play a part in PBCTV compromise.  
Figure 2 shows the BCS patients categorised according to the index quadrant of their tumour. Over 
50% of patients had tumours that were situated within the upper outer quadrant. No statistically 
significant difference was detected between index quadrant groups for 95% isodose coverage, mean 
heart NTDmean, mean LAD NTDmean and mean LADmax (see Table 1). 60% of patients who underwent 
BCS had tumours were situated in the upper half of the breast, 21% in the lower half and 19% were 
centrally located. No statistically significant difference was noted between the 95% isodose 
coverage, mean heart NTDmean, mean LAD NTDmean and mean LADmax of patients with upper half vs 
lower half tumours nor inner vs outer half tumours, although mean LAD NTDmean and LADmax were 
greater in patients with lower and inner half tumours (see Tables 2 and 3). 
There was no statistically significant difference in mean heart NTDmean (Gy) between patients who 
underwent BCS and those who underwent mastectomy: 0.8 (0.2) vs 0.8 (0.4), p=0.6. However, mean 
LAD NTDmean and LADmax (Gy) were significantly greater for patients who underwent mastectomy: 5.9 
(3.6) vs 8.7 (5.3), p=0.04 and 38.2 (11.3) vs 45.5 (3.6), p< 0.01. 
 
Discussion 
This study quantifies the doses to the heart and LAD of left-sided breast cancer patients receiving 
tangential field radiotherapy with MLC at this centre in 2010. It also assesses the impact of this 
cardiac shielding on target tissue coverage. Our data demonstrate a further reduction in cardiac 
doses from those reported by Taylor et al. in 2006 [11], and fit with the progressive reduction in 
doses seen since the 1970s (see Table 4), reflecting both the increased awareness of the need to 
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reduce cardiac doses in left breast radiotherapy, coupled with improvements in radiotherapy 
techniques (none of these historical studies used cardiac shielding). 
Although both mean heart and LAD doses are lower in this study than has previously been reported, 
the reduction in mean heart dose (65%) has been more dramatic than for mean LAD dose (12%). This 
phenomenon can be explained by the way in which MLC cardiac shielding is positioned. Although 
MLC leaves were used to shield the myocardium, the LAD frequently lies outside the shielded region 
a) because it is not routinely identified as an organ at risk and b) because it is the most anteriorly 
placed cardiac substructure. The net effect of this is that much of the LAD may sit in the penumbra 
region of the radiation field (see Figure 3), thus giving higher and more heterogeneous mean LAD 
doses than might be anticipated. Reducing the radiation dose to cardiac tissues in left-sided breast 
cancer patients frequently necessitates a trade-off between the treatment of target tissue and 
avoidance of OAR: a judgement which clinicians make on a routine basis. There are two main factors 
which need to be considered in order to weigh up this trade-off: the risk of local relapse (LR) and the 
risk of radiation-related heart disease (RRHD). The risk of LR is increased by factors such as young 
age [16-19], high tumour grade [19], the presence of extensive ductal carcinoma in situ (DCIS) [17] 
and negative ER status [20], and particular caution should be used when compromising target tissue 
coverage in these groups of patients.  To help with this problem, nomograms have been developed 
to assess the risk of ipsilateral breast recurrence, such as that from the EORTC 22881-10882 boost 
versus no boost trial [21]. A key question, however, is ‘What is the effect of reducing target tissue 
coverage on the risk of LR?’. Data strongly suggest that the majority of LRs in BCS patients occur in 
the vicinity of the original tumour [22-25], and therefore compromising PBCTV coverage is likely to 
have a proportionately greater effect on the risk of LR than compromising WBCTV. Data from the 
START Trial A generated a γ value for tumour control  of 0.2 (the γ value represents the percent 
increase in effect per percent increase in total dose delivered in 2Gy fractions) [26], suggesting that 
low level underdosing of target tissue in breast patients may not have a measurable impact on local 
control. Although partial external beam breast irradiation is being investigated in a number of 
ongoing trials (IMPORT LOW, NSABP B-39, RAPID), whole breast radiotherapy nevertheless remains 
the current standard after BCS. Patterns of LR after mastectomy are much less well understood, and 
in view of this there is currently insufficient evidence to support any compromise of target tissue 
coverage in patients requiring chest wall radiotherapy. This restriction on compromising target 
tissue coverage when irradiating the chest wall would be expected to lead to higher mean heart and 
LAD doses, and our data support this. 
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Meanwhile, consideration must be given to factors which increase the risk of RRHD, including dose 
[6,27,28], young age [27,29] and pre-existing ischaemic heart disease [3,6]. There is also evidence 
that conventional cardiac risk factors such as hypertension, diabetes, cholesterol and smoking may 
increase risk [6,30-32]. However, although there have been clear reductions in the doses of radiation 
delivered to the heart and LAD during tangential radiotherapy over the past 40 years, recent 
evidence suggests that there is no threshold dose to the heart below which the risk of RRHD ceases 
to exist [6]. In addition, hypofractionated breast radiotherapy regimens are now standard in the UK 
[2012 Royal College of Radiologists audit], but some have questioned whether the larger fraction 
sizes used in these schedules will have a negative impact on cardiac toxicity in view of the presumed 
low α/β ratio of the heart. Recent work suggests, however, that these fears are unfounded and that 
the most popular hypofractionated regimens in fact spare heart tissue relative to 2Gy schedules, 
assuming  an α/β ratio for the heart of ≥ 1.5Gy and assuming late cardiac effects are not sensitive to 
total treatment time [33]. Remaining unanswered questions include which cardiac substructure is 
the most radiosensitive (and therefore which should be used for evaluating tolerance doses) and the 
effect of cardiotoxic systemic therapies on RRHD in breast cancer patients.  
The absence of a threshold dose implies that all patients can benefit from reducing heart doses in 
breast radiotherapy. As such, it is important that the target vs OAR trade-off is optimised. A first step 
towards accomplishing this would be routine outlining of target tissues and OAR in breast 
radiotherapy. We intend to modify our practice firstly by introducing routine outlining of the tumour 
bed (and expansion to a PBCTV). We propose to do this in all patients regardless of tumour bed 
position as our findings suggest that cardiac doses are not simply a function of the position of the 
tumour bed within the breast. In addition, the use of alternative radiotherapy techniques (such as 
breath-hold or prone treatment) makes it possible to reduce cardiac doses without the need to 
compromise target tissue coverage. Prone breast radiotherapy may reduce cardiac doses in larger 
breasted women [15], however, questions remain over its reproducibility [34]. Deep inspiratory 
breath-hold techniques significantly reduce the dose to cardiac structures [35-37], and although 
their use across Europe continues to increase [7], there is currently only very limited UK uptake 
[2012 Royal College of Radiologists audit]. Treating a smaller target volume (partial breast 
irradiation), using either external beam radiotherapy or intraoperative treatment, is being 
investigated in a number of Phase III clinical trials [38], and these techniques may further reduce 
cardiac doses. Finally, it is only by avoiding adjuvant breast radiotherapy altogether that there can 
be no risk of RRHD and there may be a population of patients in whom the recurrence risk is so low 
that radiotherapy after BCS can be omitted. This is being investigated in the PRIME trial [39] and 
long-term recurrence and survival data from this study are awaited.  
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We acknowledge that our study has limitations. Patient numbers were small, however, consecutive 
patients were analysed to minimise the effect of this and improve representativeness. The 
imbalance in patient numbers when stratified by index quadrant hindered subgroup analysis. Steps 
were taken to minimise delineation errors. For LAD outlining we used a standard method, as defined 
by Taylor et al [5], and additionally all volumes were drawn by the same radiation oncologist and 
random cases verified by a second radiation oncologist. Uncertainty in tumour bed delineation was 
minimised by routine placement of tumour bed clips at surgery. 
Conclusion 
This study demonstrates a continued reduction in radiation doses to cardiac tissues through the use 
of MLC. However, this fall in cardiac doses has led to target tissue coverage being compromised. We 
recommend the use of formal target volume definition in combination with individualised 
assessments of the risk of LR in order guide the placement of field borders and the use of MLC. 
Techniques which minimise the need for a compromise between target tissue and OAR coverage 
(such as breath-holding) should be pursued as a matter of priority. 
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Figure 1: Digitally rendered radiograph (DRR) demonstrating how multileaf collimation (MLC) 
used for shielding cardiac tissue risks simultaneously shielding target tissue. 
Key: Orange wireframe – heart; small coloured dots – tumour bed clips; large yellow 
dot – isocentre  
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Figure 2: BCS patients categorised according to index quadrant of tumour 
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Figure 3: Axial CT slice demonstrating LAD sitting within penumbra region of left breast 
tangential radiotherapy fields 
 Key: Orange colourwash – LAD, dark green colourwash – LAD plus 1cm margin 
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Table 1 
Target volume isodose coverage (%) and cardiac dose parameters (Gy) stratified according to index quadrant 
of tumour (standard deviations in brackets). 
Tumour quadrant WBCTV V95% PBCTV V95% Heart NTDmean LAD NTDmean LADmax 
Central 
n=9 
89 (9) 95 (7) 0.8 (0.2) 5.2 (3.5) 33.5 (14.8) 
Lower inner 
n=4 
86 (8) 99 (1) 0.8 (0.3) 5.7 (1.4) 43.0 (1.2) 
Lower outer 
n=6 
91 (6) 99 (1) 0.8 (0.2) 8.1 (2.9) 42.6 (6.6) 
Upper inner 
n=3 
85 (2) 97 (2) 0.9 (0.4) 6.0 (2.9) 39.3 (5.3) 
Upper outer 
n=26 
90 (5) 97 (5) 0.7 (0.3) 5.6 (4.1) 38.0 (11.7) 
p 0.46 0.67 0.87 0.62 0.53 
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Table 2 
Target volume isodose coverage (%) and cardiac dose parameters (Gy) stratified according to index half of 
tumour (upper vs lower) (standard deviations in brackets). 
Tumour half WBCTV V95% PBCTV V95% Heart NTDmean LAD NTDmean LADmax 
Upper 
n=29 
89 (5) 97 (4) 0.8 (0.3) 5.7 (3.9) 38.1 (11.1) 
Lower 
n=10 
89 (7) 99 (1) 0.8 (0.2) 7.2 (2.6) 42.7 (5.0) 
p 0.84 0.82 0.71 0.09 0.42 
 
  
Breast radiotherapy cardiac doses with MLC 
 
Table 3 
Target volume isodose coverage (%) and cardiac dose parameters (Gy) stratified according to index half of 
tumour (outer vs inner) (standard deviations in brackets). 
Tumour half WBCTV V95% PBCTV V95% Heart NTDmean LAD NTDmean LADmax 
Outer 
n=25 
90 (5) 97 (4 0.8 (0.4) 6.6 (4.9) 39.9 (10.8) 
Inner 
n=13 
88 (6) 98 (1) 0.8 (0.3) 7.2 (2.8) 43.1 (5.1) 
p 0.41 0.84 0.62 0.16 0.83 
  
Breast radiotherapy cardiac doses with MLC 
 
 
Table 4 
Cardiac doses (Gy) in left breast radiotherapy since the 1970s (standard deviations in brackets, where 
available). 
Period Mean heart dose Mean LAD dose LADmax 
1970s (Sweden) [5] 13.3 31.8 52.0 
1990s (Sweden) [5] 4.7 21.9 51.5 
2006 (UK)  [11] 2.3 (0.7) 7.6 (4.5) 35.2 (8.8) 
2010 (UK) 0.8 (0.3) 6.7 (4.3) 40.3 (10.1) 
 
